Complications of Cancer Chemotherapy. The Special Case of Hormones

  • J. C. Heuson
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 49)


Side effects of hormones given for the treatment of neoplastic diseases, such as for example breast cancer, depend upon mechanisms quite different from those operating with other chemotherapeutic agents. This is precisely because hormones are usually not cytotoxic and that their antitumor efficacy appears to be based more on regulatory mechanisms than on cytotoxicity.


Breast Cancer Advanced Breast Cancer Cancer Chemotherapy Mammary Cancer Prolactin Secretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cole, M. P., Jones, C. T. A., Todd, I. D. H.: A new anti-oestrogenic agent in late breast cancer. An.early clinical appraisal of ICI 46474. Brit. J. Cancer 25, 270 (1971).PubMedCrossRefGoogle Scholar
  2. Ford, H. T.: Durabolin and Deca-Durabolin in the treatment of advanced mammary cancer. A. R. Brit. Emp. Cancer Campgn 37, 267 (1959).Google Scholar
  3. Gallez, GH., Heuson, J. C., Waelbroeck, CH.: Growth-stimulating effect of Nafoxidine on rat mammary tumor after ovariectomy. Europ. J. Cancer 9, 699 (1973).CrossRefGoogle Scholar
  4. Goldenberg,I. S., Waters, M. N., Ravdin, R. S., Ansfield, F. J., Segaloff, A. : Cooperative Breast Cancer Group: Androgenic therapy for advanced breast cancer in women. J. Amer. med. Ass. 223, 1267 (1973).CrossRefGoogle Scholar
  5. Gordan, G. S., Wessler, S., Avioli, L. V. : Calusterone in the therapy for advanced breast cancer. J. Amer. med. Ass. 219 , 483 (1972).CrossRefGoogle Scholar
  6. Helman, P., Bennett, M. B.: Hormone therapy of breast cancer with special reference to Masteril therapy. S. Afr. med. J. 46, 1195 (1972).PubMedGoogle Scholar
  7. Heuson, J. C., Coune, A., Staquet, M.: European Breast Cancer Group: Clinical trial of Nafoxidine (U-l 1.100 A) in advanced breast cancer. Europ. J. Cancer 8, 387 (1972).CrossRefGoogle Scholar
  8. Heuson, J. C., Waelbroeck, CH., Legros, N., Gallez, GH., Robyn, C., L’hermite, M.: Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-Br-a-ergocryptine (CB 154), an inhibitor of prolactin secretion, and by Nafoxidine (U-l 1,100 A), an estrogen antagonist. Hormones and Antagonists. Gynec. Invest. 2, 130 (1971/72)Google Scholar
  9. Heuson, J. C.: The role of prolactin inhibition in the treatment of advanced breast cancer. Mammary Cancer and Neuroendocrine Therapy. B. STOLL, Ed. p. 349. London: Butterworths 1974.Google Scholar
  10. Karhausen, L., Kenis, Y., Smulders, J., Parmentier, R.: Hypercalcémie et néphrocalcinose. Etude de quartre cas de cancer du sein avec métastases osseuses. Acta clin. belg. X, 295 (1955).Google Scholar
  11. L’hermite, M., Heuson, J. C., Robyn, Cl.: Unpublished data.Google Scholar
  12. Pearson, O. H., West, C. D., Hollander, Y. P.,Treves, N. E.: Evaluation of endocrine therapy for advanced breast cancer. J. Amer. med. Ass. 154, 234 (1954).CrossRefGoogle Scholar
  13. Pearson,O. H., Llerena, O., Llerenà, L.,Molina, A., Butler, T.: Prolactin-ependent rat mammary cancer: a model for man? Trans. Ass. Amer. Phycns 82, 225 (1969).Google Scholar
  14. Petit, J. C., Klein, TH., Rodier, D.: Traitement hormonal du cancer du sein avancé par le propionate de drostanolone. Bull. Cancer 58, 511 (1971).PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1974

Authors and Affiliations

  • J. C. Heuson
    • 1
  1. 1.Service de Médecine et d’InvestigationClinique de l’Institut J. BordetBruxellesBelgium

Personalised recommendations